Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 4973-4986

  Cucchi, Ulisse ^a   Gianellini, Laura M ^a   De Ponti, Anna ^a,b   Sola, Francesco ^a   Alzani, Rachele ^a   Patton, Veronica ^a   Pezzoni, Alice ^a   Troiani, Sonia ^a   Saccardo, Maria B ^a   Rizzi, Simona ^a   Giorgini, Maria L ^a   Cappella, Paolo ^a   Beria, Italo ^a   Valsasina, Barbara ^a  

^a BU Oncology   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Antitumor activity; Biomarker; PLK1; TCTP

Indexed keywords

CALCIUM BINDING PROTEIN; POLO LIKE KINASE 1; PROTEIN TCTP; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION;

ANIMALS; BONE NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; FEMALE; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; OSTEOSARCOMA; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 78751477698     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Archambault V and Glover DM: Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 4: 265-275, 2009.
2. Barr FA, Silljé HH and Nigg EA: Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 6: 429-440, 2004.
3. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL and Ferris DK: Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 234: 397-405, 1997.
4. Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, Pliquett U, Neumann E and Zeuzem S: Tumor regression by combination antisense therapy against Plk 1 and Bcl-2: Oncogene 22: 69-80, 2003.
5. Strebhardt K and Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6: 321-330, 2006.
6. Strebhardt K: Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9: 643-660, 2010.
7. Schöffski P: Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14: 559-570, 2009.
8. Roshak AK, Capper EA, Imburgia C, Fornwald J, Scott G and Marshall LA: The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal 12: 405-411, 2000.
9. Hornig NC and Uhlmann F: Preferential cleavage of chromatinbound cohesin after targeted phosphorylation by polo-like kinase. EMBO J 23: 3144-3153, 2004.
10. Yuan J, Eckerdt F, Bereiter-Hahn J, Kurunci-Csacsko E, Kaufmann M and Strebhardt K: Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 21: 8282-8292, 2002.
11. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T and Osada H: M-phase kinases induce phosphodependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci USA 101: 4419-4424, 2004.
12. Nakajima H, Toyoshima-Morimoto F, Taniguchi E and Nishida E: Identification of a consensus motif for P1k (polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J Biol Chem 275: 25277-2528, 2003.
13. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M and Nakagawara A: Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279: 25549-25561, 2004.
14. Hansen DV, Loktev AV, Ban KH and Jackson PK: Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC inhibitor Emil. Mol Biol Cell 15: 5623-5634, 2004.
15. Olmos D, Swanton CJ and de Bono J: Targeting polo-like kinase: learning too little too late? J Clin Oncol 26: 5497-5499, 2008.
16. Yarm FR: Plk phosphorylation regulates the microtubulestabilizing protein TCTP. Mol Cell Biol 22: 6209-6221, 2002.
17. Johnson TM, Antrobus R and Johnson LN: Plk1 activation by Ste20-like kinase (SIk) phosphorylation and polo-box phosphopeptide binding assayed with the substrate translationally controlled tumor protein (TCTP). Biochemistry 47: 3688-3696, 2008.
18. Beria I, Ballinari D, Bertrand JA, Borghi D, Bossi RT, Brasca MG, Cappella P, Caruso M, Ceccarelli W, Ciavolella A, Cristiani C, Croci V, De Ponti A, Fachin G, Ferguson RD, Lansen J, Moll JK, Pesenti E, Posteri H, Perego R, Rocchetti M, Storici P, Volpi D and Valsasina B: Identification of 4,5-dihydro1H-pyrazolo(4,3-h)quinazoline derivatives as a new class of orally and selective polo-like kinase 1 inhibitors. J Med Chem 13: 3532-3551, 2010.
19. Sawyers C: Targeted cancer therapy Nature 432: 294-297,2004.
20. Frank R and Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 7: 566-580, 2003.
21. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauen M, Adolf GR, Kraut N, Peters JM and Rettig WJ: BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316-322, 2007.
22. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR and Laquerre SG: Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK-461364A, including differential effect on apoptosis. Cancer Res 69: 6969-6977, 2009.
23. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P and Adolf GR: BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Cancer Res 15: 3094-3102, 2009.
24. Park JE, Li L, Park J, Knecht R, Strebhardt K, Yuspa SH and Lee KS: Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay. Proc Natl Acad Sci USA 106: 1725-1730, 2009.